COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

bioRxiv posts many COVID19-related papers. A reminder: they have not been formally peer-reviewed and should not guide health-related behavior or be reported in the press as conclusive.

19,458 Articles (14,982 medRxiv, 4,476 bioRxiv)

Most recent first Previous |  Page 7: Articles 61-70  | Next

Opsonization by non-neutralizing antibodies can confer protection to SARS-CoV-2 despite Spike-dependent modulation of phagocytosis
Bahnan, W., Wrighton, S., Sundwall, M., Bläckberg, A., Larsson, O., Höglund, U., Khakzad, H., Godzwon, M., Walle, M., Elder, E., Happonen, L., Andre, O., Kumra Ahnlide, J., Hellmark, T., Wendel-Hansen, V., Wallin, R. P., Malmström, J., Malmström, L., Ohlin, M., Rasmussen, M., Nordenfelt, P.
10.1101/2021.10.14.464464 — Posted: 2021-10-15
Deep learning based on stacked sparse autoencoder applied to viral genome classification of SARS-CoV-2 virus
Coutinho, G. G. F., Camara, G. B. M., Barbosa, R. d. M., Fernandes, M. A. C.
10.1101/2021.10.14.464414 — Posted: 2021-10-15
Impact Of Adaptive Natural Killer Cells, KLRC2 Genotype And Cytomegalovirus Reactivation On Late Mortality In Patients With Severe Covid-19 Lung Disease
Jaiswal, S. R., Arunachalam, J., Bhardwaj, A., Saifullah, A., Lakhchaura, R., Soni, M., Bhagwati, G., Chakrabarti, S.
10.1101/2021.10.11.21264805 — Posted: 2021-10-14
Evaluation of real-life use of Point-Of-Care Rapid Antigen TEsting for SARS-CoV-2 in schools for outbreak control (EPOCRATES)
Blanchard, A. C., Desforges, M., Labbe, A.-C., Nguyen, C. T., Petit, Y., Besner, D., Zinszer, K., Seguin, O., Laghdir, Z., Adams, K., Benoit, M.-E., Leduc, G., Longtin, J., Ragoussis, I., Buckeridge, D. L., Quach, C.
10.1101/2021.10.13.21264960 — Posted: 2021-10-14
Mechanism of optimal time-course COVID-19 vaccine prioritization based on non-Markovian steady-state prediction
Feng, M., Tian, L., Zhou, C.
10.1101/2021.10.11.21264836 — Posted: 2021-10-14
A Rapid Bead-Based Assay For Screening Of SARS-CoV-2 Neutralising Antibodies
SL, S., Darvin, P., Chandrasekharan, A., Varadarajan, S. N., Divakaran, S. J., Easwaran, S., Nelson-Sathi, S., Perunthottathu, U. K., Jones, S., Joseph, I., Pillai, R. M., TR, S. K.
10.1101/2021.10.13.464050 — Posted: 2021-10-14
Soluble angiotensin-converting enzyme 2 as a prognostic biomarker for disease progression in patients infected with SARS-CoV-2
Diaz Troyano, N., Gabriel Medina, P., Weber, S., Klammer, M., Barquin-DelPino, R., Castillo-Ribelles, L., Esteban, A., Hernandez-Gonzalez, M., Ferrer-Costa, R., Pumarola, T., Rodriguez Frias, F.
10.1101/2021.10.13.21264901 — Posted: 2021-10-14
Disparities in SARS-CoV-2 exposure: evidence from a citywide seroprevalence study in Holyoke, Massachusetts, USA
Matias, W. R., Fulcher, I. R., Sauer, S. M., Nolan, C. P., Guillaume, Y., Zhu, J., Molano, F. J., Uceta, E., Collins, S., Slater, D. M., Sanchez, V. M., Moheed, S., Harris, J. B., Charles, R. C., Paxton, R. M., Gonsalves, S. F., Franke, M. F., Ivers, L. C.
10.1101/2021.10.13.21264975 — Posted: 2021-10-14
A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses
Wang, P., Casner, R. G., Nair, M. S., Yu, J., Guo, Y., Wang, M., Chan, J. F. W., Cerutti, G., Iketani, S., Liu, L., Sheng, Z., Chen, Z., Yuen, K.-Y., Kwong, P. D., Huang, Y., Shapiro, L., Ho, D. D.
10.1101/2021.10.13.464307 — Posted: 2021-10-14
Effects of Side-Effect Risk Framing Strategies on COVID-19 Vaccine Intentions in the United States and the United Kingdom: A Randomized Controlled Trial
Sudharsanan, N., Favaretti, C., Hachaturyan, V., Baernighausen, T., Vandormael, A.
10.1101/2021.10.12.21264877 — Posted: 2021-10-14

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).